ITM - Key Persons
Job Titles:
- Head of Global Human Resources
Andrea Schwarz-Dymiński, BA has been Head of Human Resources at ITM since 2016. Prior to this, Andrea held a leading position of HR Director at MorphoSys AG and was a Manager Human Resources at TRION Pharma GmbH.
Andrea is an experienced Human Resources professional with a demonstrated history in the pharmaceutical industry. Andrea is a certified Business Coach & Trainer, a certified HR Manager and holds a Bachelor in International Business Administration from the European Business School.
Job Titles:
- Chief Financial Officer
- Chief Financial Officer ITM Group
Dr. Klaus Maleck joined ITM as Chief Financial Officer in June 2021. He has over 25 years of experience as a Biopharmaceutical Industry Executive.
Prior to joining ITM, he served as CEO of TETEC AG, a fully integrated regenerative medicine developer and manufacturer within the Aesculap/B Braun group, which grew under Klaus from 30 employees to one of the largest manufacturers in the field. This followed roles as CFO and CBO at Evotec AG, where he drove key corporate development events, including the Nasdaq listing of the company. Earlier in his career, Klaus was Co-Founder and CFO of BioGeneriX AG, the Biosimilars business of Ratiopharm, and a senior consultant to the life science industry with McKinsey & Co. He began his professional career as a Research Scientist at the Novartis Biotechnology and Genomics Center in NC (USA).
Klaus holds an MBA degree, as well as a master's degree in Biotechnology from the ESBS in Strasbourg (France), and a PhD in Biochemistry from the Max Planck Institute in Cologne (Germany).
Job Titles:
- Chief Scientific Officer & Managing Director ITM Medical Isotopes & ITM Oncologics
- Head of Product Management
Dr. Konstantin Zhernosekov joined ITM as Head of Product Management in 2012, and is responsible for developing and controlling strategic marketing concepts and marketing authorization procedures, respectively. Prior to his work at ITM, Konstantin worked as a Group Leader at the Paul Scherrer Institute (Switzerland) where he acquired extensive expertise in radio- and radiopharmaceutical chemistry, bringing radioisotope technologies to clinical applications. From 2006 to 2009, he earned his first spurs as Postdoc at the Technical University of Munich (TUM).
Job Titles:
- Chief Operating Officer & Managing Director ITM Medical Isotopes / Production / Research & Development
- Head of Production and R & D
Dr. Mark Harfensteller joined ITM as Head of Production and R&D in 2008. In 2016, he became Managing Director of ITM Medical Isotopes. Under Mark's leadership, the company established an industrial and GMP compliant production, meeting the demand of the rapidly expanding radioisotope market. Prior to his work at ITM, Mark successfully completed a project at the Institute of Machine Tools and Industrial Management (TUM), focusing on the development and production of alpha-emitter, 225 Ac, via the irradiation of 226 Ra in a cyclotron. The project has been nominated for the "Deutscher Zukunftspreis".
Job Titles:
- Managing Director ITM Medical Isotopes
- Managing Director of ITM 's Subsidiary ITM Medical Isotopes
Dr. Richard Henkelmann was appointed Managing Director of ITM's subsidiary ITM Medical Isotopes in October 2007. Richard is in charge of R&D, production, and supervision of radiation protection. Thus, he holds a key role when dealing with regulatory authorities, leading institutions of the Technical University of Munich (TUM), and the Bavarian Government. As former Chief Academic Director of the Radiochemical Institute TUM, Richard has constantly been involved at the forefront of scientific development with regards to neutron activation analysis, radiation safety and measurement as well as isotope production.
Job Titles:
- Chief Business Officer ITM Group
Dr. Sebastian Marx joined ITM in 2008 and has since contributed significantly to the company's growth. He has held various positions in research and development, production, quality, product management and partner management at ITM and was appointed Head of Sales in 2014. Together with his team, Sebastian helped build the company's international customer base and distribution partner network, which greatly contributed to ITM securing its role as a world market leader in the radiopharmaceutical field. In addition to his industry contacts, deep knowledge of the production and development of radioisotopes, Sebastian is well versed in the fundamentals of analytics, radiochemistry, and nuclear medicine. He holds a PhD in chemistry from the Technical University of Munich (TUM), Germany.
Dr. Wolfgang Seidel joined ITM in September 2020 as Head of Corporate Quality of the recently established Corporate Quality department.
Prior to his work at ITM, Wolfgang held a number of quality control, quality assurance and quality management positions both in major pharmaceutical companies as well as biotechnology companies such as Merck KGaA, Procter & Gamble, Metabion and Medigene. With more than 20 years of experience in pharma research as well as development and commercial production, Wolfgang has developed a deep understanding of product lifecycle management and the underlying legal framework, a broad expertise of the pharmaceutical and biotechnology industry as a whole, as well as development, implementation and management of quality systems to assure compliance and to foster quality culture.
Wolfgang holds a PhD in Food Chemistry from the Ludwig-Maximilians University of Munich (LMU) (Germany).
Job Titles:
- Member of the Supervisory Board
- Member of the Vice Chairman of the Board
- Vice Chairman of the Board
Gunther obtained an MA in Economics and an MBA. Previously, Gunther held several managing functions such as CFO of Hugo Boss AG, Investment Banking at Goldman Sachs, and Managing Director Germany at Oliver Wyman & Company. Moreover, he has been a non-executive member of several boards since 1996. Gunther became a member of ITM´s supervisory board in 2016 and Vice Chairman of the Board in 2020.
Job Titles:
- Head of Corporate Communications
Julia Hofmann joined ITM as Head of Corporate Communications in October 2021. She has over 20 years of experience in leading PR/IR positions in publicly listed, technology-based companies. Prior to joining ITM, Julia was Executive Director at MC Services, a leading international PR/IR agency focused on the biotech industry. Before that, she served as Head of Public Relations & Investor Relations at the immuno-oncology company Medigene AG where she was responsible for the company's internal and external communication and supported several capital market transactions. Previously, Julia led the PR/IR department of buecher.de AG, a leading German e-commerce company. Julia started her career at the global PR firm Weber Shandwick where she worked for pharma companies like Essex Pharma (today MSD) and major internet firms like Amazon.com. For nearly 10 years, she was involved in the reputation management for the pharmaceutical industry at vfa, Association of Research-Based Pharmaceutical Companies.
Manuel holds an MA in finance from the University of St. Gallen and the Fudan University in Shanghai. He is a CFA and also a CAIA charterholder. After having worked for The Boston Consulting Group and a private equity firm, Manuel structured and now runs the investments of Dr Uli Sigg, the former Swiss ambassador to China. Manuel sits on numerous boards of directors of technology and financial services companies.
Job Titles:
- Founder and Chairman of Portland Holdings
Michael joined the supervisory board in May 2019. Michael is founder and chairman of Portland Holdings, a privately held investment company headquartered in Burlington, Ontario, Canada. The company is committed to investing in businesses active in strong, long-term growth industries that also seek to improve the social well-being of the communities in which they operate. The philosophy of Michael Lee-Chin and Portland Holdings is to "do well and do good" - building strong businesses that are giving back to society. For his entrepreneurial and philanthropic work, Michael has received numerous awards and honors.
Oliver Buck is the founder of ITM. From 2005 to 2011, Mr. Buck devoted his time and expertise to the initial build-up of ITM as its chief executive officer and subsequently has served as a member of ITM's supervisory board and as a senior advisor to the company since 2012. His main focus in this function has been in supporting the company in the expansion of its strategic, technological and global footprint.
He holds a graduate degree (Dipl.-Phys.) in theoretical physics from the Technical University of Munich (TUM) and is an accomplished serial entrepreneur with a track record of pioneering work across a range of technologies and industries. Since 2002 his main focus has been in the life-science and radiopharmaceutical space.
Oliver Buck is an alumnus of the American Council on Germany (ACG)/Atlantikbrücke's "Young Leaders Program", of the German Federal Academy for Security Policies "(BakS) Core Seminar" and of the Singularity Universities (SU) Executive Program. He also is a co-founder of Global Bridges e.V. and a co-founder and member of the Board of Trustees of the International Centers for Precision Oncology (ICPO) Foundation.
Job Titles:
- Head of Controlling & Administration
Job Titles:
- Chief Medical Officer ITM Oncologics
Philip E Harris, BSc MB BCh PhD FRCP FRSB was appointed Chief Medical Officer of ITM in June 2018. He is responsible for providing clinical leadership to ITM's radiopharmaceutical development platform. With more than 16 years of leadership experience in industry, Philip has contributed greatly to the development of various theranostic radionuclide therapy platforms in Oncology. His previous industry positions include Director of Global Medical Affairs at Pharmacia, Senior Director of Clinical Development at Pfizer, and Vice President at Ipsen. Philip is a distinguished clinical endocrinologist and general physician, with a strong academic background. Prior to moving into industry, he held an academic consultant appointment at King's College Hospital, London in internal medicine and adult endocrinology.
Philip holds a Bachelor of Medicine & Surgery and a PhD from the University of Wales (UK).
Stefan studied mechanical engineering and obtained his master's degree at the Technical University of Munich. Subsequently, he earned his MBA at Clark University (Mass./USA), majoring in Corporate Finance and Marketing. He started his professional career at Bain & Company. Today, Stefan is co-founder of Goetzpartners, an independent advisory firm for all key issues of entrepreneurial activities as well as co-founder of the private equity company, DIEP - Deutsche Invest Equity Partners. Stefan joined the Supervisory Board of ITM in April 2020.
Job Titles:
- CEO
- Member of the Executive Board
- Chief Executive Officer ITM Group
- Dr. Klaus Maleck ( CFO ), Dr. Sebastian Marx ( CBO )
Steffen Schuster, Dipl.-Kfm. has been Chief Executive Officer of ITM since December 2011. During his time with ITM, Steffen has greatly expanded the development and production of medical radioisotopes and radiopharmaceuticals internationally and successfully led ITM from a pure radioisotope manufacturer to a global biotechnology and radiopharmaceutical company. In addition, he has concluded important strategic partnerships, secured relevant equity and debt financing, including a loan from the European Investment Bank, and opened new sites in Germany and USA as part of ITM's growth course.
Prior to his work at ITM, Steffen was a General Partner at TVM Capital. Before that, he served as the Chief Financial Officer of the publicly listed cycos AG. Earlier in his career, Steffen worked for the Siemens Network Division where he held a variety of leading roles including international M&A as well as Co-founder of the Mustang Ventures fund with headquarters in Silicon Valley where he acted as Managing Director and Investment Partner.
Steffen received a Master's Degree in Economics (Dipl.-Kfm.) from the University of Saarbrücken (Germany).
Tadd joined the supervisory board in June 2021. He is the Founder and Managing Partner of Petrichor Healthcare Capital Management, a private equity firm focused on the healthcare sector. Tadd was formerly a Managing Director at OrbiMed Advisors and Vice President at Fortress Investment Group. Tadd sits on numerous boards of directors of life sciences companies. He holds an A.B. (Artium Baccalaureus) in Biology from Princeton University.
Job Titles:
- Chairman of the Supervisory Board
- Member of the Chairman of the Board
- Expert
- Member of ITM 's Supervisory Board
Udo J. Vetter has served as a member of ITM's supervisory board since 2006 and has been its chairman since 2007. As one of the founding fathers of the company, he has made significant contribution to the establishment and development of ITM as a vertically integrated biopharmaceutical company through his broad pharmaceutical expertise and strategic advice.
Since 1987, Mr Vetter has held various senior management positions at the Vetter Group. Since 2008 he is chairman of the advisory board of Vetter Pharma-Fertigung GmbH & Co. KG. In 2003 Mr. Vetter established the investment company UV-Cap GmbH & Co. KG and serves as its managing director to present. From 1983 to 1992 he was vice president for licensing and production at Martec Inc. and president of Vetter Pharma-Turm Inc. Previously he worked for five years as a pharmacist at the pharmaceutical company Schering-Plough Corp. (now Merck & Co Inc.) and set up production facilities in Puerto Rico.
Mr. Vetter is a member of the supervisory board of Gerresheimer AG and of the expert association ISPE (International Society of Pharmaceutical Engineers). He is also a member of the board of directors at Gland Pharma Ltd., India. He was chairman of the university council of the University Albstadt-Sigmaringen until 2018, receiving the title Honorary Senator from the educational institution in the same year. Since 2019, he is president of European Family Businesses (EFB). He obtained a degree in Clinical Pharmacy at the University of Washington in Seattle.